One of the key trials, SUSTAIN 6, found that semaglutide lowered the risk of major cardiovascular events in high-risk patients with diabetes
We'll work with you to establish healthy habits that complement your treatment and support long-lasting success
FDA-approved indications: To lower the risk of major cardiovascular events and death in adults with heart disease
Traditionally, once physicians put their patients on this regimen, it is considered lifelong therapy. Although the arrival of GLP-1RAs has dramatically improved the treatment landscape for many with T2D, leveraging the therapy to de-escalate treatment is rather uncommon, Dr
Nausea is common, especially during dose increases
Some people benefit from ongoing treatment For those who often regain weight, have metabolic conditions or have strong appetite drivers, staying on treatment long term may offer stability